

## Regimen Reference Order – THOR - durvalumab

ARIA: LUNG – [durvalumab]

Planned Course: Every 2 weeks for 12 months

Indication for Use: Non-Small Cell Lung Cancer Adjuvant

Drug Alert: Immune Checkpoint Inhibitor

CVAD: At Provider's Discretion

### **Proceed with treatment if:**

- *ANC equal to or greater than  $1.5 \times 10^9/L$  AND Platelets equal to or greater than  $50 \times 10^9/L$*
- *AST/ALT less than 3 times the upper limit of normal*
- *Total bilirubin less than 1.5 times the upper limit of normal*
- *Creatinine clearance greater than 30 mL/minute*
- ❖ **Contact Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – THOR - durvalumab

Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
durvalumab	10 mg/kg	IV in 250 mL normal saline over 60 minutes Use 0.2 or 0.22 micron filter <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

**In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'**

### REQUIRED MONITORING

All Cycles

- CBC, full biochemistry, electrolytes, TSH and glucose as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline
- No observation period is required
- Patient can be discharged from treatment room if stable whether they had a reaction or not

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### DISCHARGE INSTRUCTIONS

- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
  - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

### ADDITIONAL INFORMATION

- durvalumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated
- Administration site restrictions are in place for durvalumab. Health Canada mandates that dispensing pharmacist and nurse must review manufacturer slide deck